Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

NCT04252365 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Nsclc

Interventions

DRUG: Sintilimab
DRUG: Pembrolizumab

Sponsor

Guangdong Association of Clinical Trials